CURMATE 95 : A Powerful combination of Curcumin & Piperine 100:1 ratio
Abstract: Nonalcoholic fatty liver disease (NAFLD) poses a significant health challenge with associations to liver-related morbidity, mortality, and cardiovascular disease. Lifestyle modifications and metabolic control are primary treatments, but their efficacy in reversing NAFLD pathogenesis varies. Curcumin, a dietary phytochemical with hepatoprotective properties, faces bioavailability challenges in clinical applications. This clinical trial aimed to enhance curcumin's effectiveness by coadministering it with piperine and evaluating its impact on serum hepatic enzymes, lipid profile, and glycemic indices in NAFLD patients.
Introduction: NAFLD, a prevalent hepatic condition, necessitates effective interventions beyond conventional treatments. Curcumin, known for its hepatoprotective activities, has shown promise in preclinical studies, but its limited bioavailability has hindered clinical applications. This study explores the combination of curcuminoids and piperine as a potential solution to enhance curcumin's bioavailability and improve outcomes in NAFLD patients.
Methods: A randomized controlled parallel-group trial included 70 subjects diagnosed with NAFLD through ultrasound. Participants were randomly assigned to receive either 500 mg curcuminoids coadministered with 5 mg piperine daily or a placebo for 12 weeks. Assessments of NAFLD severity (sonography) and hepatic function were conducted at baseline and study completion.
Results: The trial yielded promising results, with all 70 subjects completing the study. The group supplemented with curcuminoids plus piperine exhibited a significant reduction in hematocrit, erythrocyte sedimentation rate, and serum concentrations of key hepatic enzymes and lipid markers. Notably, total iron-binding capacity increased. Changes in parameters, except for albumin, did not differ significantly between groups. Importantly, the administration of curcuminoids plus piperine significantly improved NAFLD severity compared to the placebo group, indicating a potential therapeutic benefit.
